These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
383 related articles for article (PubMed ID: 18838471)
1. Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia. Malfuson JV; Etienne A; Turlure P; de Revel T; Thomas X; Contentin N; Terré C; Rigaudeau S; Bordessoule D; Vey N; Gardin C; Dombret H; Haematologica; 2008 Dec; 93(12):1806-13. PubMed ID: 18838471 [TBL] [Abstract][Full Text] [Related]
2. Treatment of primary acute myeloid leukemia: results of a prospective multicenter trial including high-dose cytarabine or stem cell transplantation as post-remission strategy. Brunet S; Esteve J; Berlanga J; Ribera JM; Bueno J; Martí JM; Bargay J; Guardia R; Juliá A; Granena A; Montserrat E; Sierra J; Haematologica; 2004 Aug; 89(8):940-9. PubMed ID: 15339677 [TBL] [Abstract][Full Text] [Related]
3. Disease biology rather than age is the most important determinant of survival of patients > or = 60 years with acute myeloid leukemia treated with uniform intensive therapy. Gupta V; Chun K; Yi QL; Minden M; Schuh A; Wells R; Brandwein J Cancer; 2005 May; 103(10):2082-90. PubMed ID: 15830348 [TBL] [Abstract][Full Text] [Related]
4. Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia: a single-institution experience. Plesa C; Chelghoum Y; Plesa A; Elhamri M; Tigaud I; Michallet M; Dumontet C; Thomas X Cancer; 2008 Feb; 112(3):572-80. PubMed ID: 18085638 [TBL] [Abstract][Full Text] [Related]
5. Single-agent laromustine, a novel alkylating agent, has significant activity in older patients with previously untreated poor-risk acute myeloid leukemia. Schiller GJ; O'Brien SM; Pigneux A; Deangelo DJ; Vey N; Kell J; Solomon S; Stuart RK; Karsten V; Cahill AL; Albitar MX; Giles FJ J Clin Oncol; 2010 Feb; 28(5):815-21. PubMed ID: 20026800 [TBL] [Abstract][Full Text] [Related]
6. Results of risk-adapted therapy in acute myeloid leukaemia. A long-term population-based follow-up study. Wahlin A; Billström R; Björ O; Ahlgren T; Hedenus M; Höglund M; Lindmark A; Markevärn B; Nilsson B; Sallerfors B; Brune M Eur J Haematol; 2009 Aug; 83(2):99-107. PubMed ID: 19385987 [TBL] [Abstract][Full Text] [Related]
7. Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approaches. Deschler B; de Witte T; Mertelsmann R; Lübbert M Haematologica; 2006 Nov; 91(11):1513-22. PubMed ID: 17082009 [TBL] [Abstract][Full Text] [Related]
8. Long-term outcomes of de novo acute myeloid leukemia in Thai patients. Niparuck P; Chuncharunee S; Ungkanont A; Udomtrupayakul U; Aungchaisuksiri P; Rerkamnuatchoke B; Jootar S; Atichartakarn V J Med Assoc Thai; 2009 Sep; 92(9):1143-9. PubMed ID: 19772172 [TBL] [Abstract][Full Text] [Related]
9. Significance of age in acute myeloid leukemia patients younger than 30 years: a common analysis of the pediatric trials AML-BFM 93/98 and the adult trials AMLCG 92/99 and AMLSG HD93/98A. Creutzig U; Büchner T; Sauerland MC; Zimmermann M; Reinhardt D; Döhner H; Schlenk RF Cancer; 2008 Feb; 112(3):562-71. PubMed ID: 18076087 [TBL] [Abstract][Full Text] [Related]
10. Comorbidities and FLT3-ITD abnormalities as independent prognostic indicators of survival in elderly acute myeloid leukaemia patients. Breccia M; Frustaci AM; Cannella L; Stefanizzi C; Latagliata R; Cartoni C; Diverio D; Guarini A; Nanni M; Rago A; Cimino G; Alimena G Hematol Oncol; 2009 Sep; 27(3):148-53. PubMed ID: 19274612 [TBL] [Abstract][Full Text] [Related]
11. Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia. Roboz GJ; Ritchie EK; Curcio T; Provenzano J; Carlin R; Samuel M; Wittenberg B; Mazumdar M; Christos PJ; Mathew S; Allen-Bard S; Feldman EJ Cancer; 2008 Nov; 113(9):2504-11. PubMed ID: 18825661 [TBL] [Abstract][Full Text] [Related]
12. The benefit of induction chemotherapy in patients age > or = 75 years. Vey N; Coso D; Bardou VJ; Stoppa AM; Braud AC; Bouabdallah R; Sainty D; Mozziconacci MJ; Lafage M; Damaj G; Blaise D; Gastaut JA; Maraninchi D Cancer; 2004 Jul; 101(2):325-31. PubMed ID: 15241830 [TBL] [Abstract][Full Text] [Related]
13. Outcome in elderly acute myeloid leukaemia. Osman H; Murray M; Egan E; O'Dwyer M Ir Med J; 2008; 101(10):307-10. PubMed ID: 19205141 [TBL] [Abstract][Full Text] [Related]
14. Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia. Giles F; Rizzieri D; Karp J; Vey N; Ravandi F; Faderl S; Khan KD; Verhoef G; Wijermans P; Advani A; Roboz G; Kantarjian H; Bilgrami SF; Ferrant A; Daenen SM; Karsten V; Cahill A; Albitar M; Mufti G; O'Brien S J Clin Oncol; 2007 Jan; 25(1):25-31. PubMed ID: 17146105 [TBL] [Abstract][Full Text] [Related]
15. What is the optimal induction strategy for older patients? Estey E Best Pract Res Clin Haematol; 2011 Dec; 24(4):515-22. PubMed ID: 22127314 [TBL] [Abstract][Full Text] [Related]